High Court Won't Hear Abilify Whistleblowers' FCA Claims
Law360 (May 29, 2018, 5:04 PM EDT) -- The U.S. Supreme Court said Tuesday it will not hear whistleblowers’ appeal of a Sixth Circuit finding that they haven’t demonstrated that pharmaceutical companies Bristol-Myers and Otsuka’s alleged off-label promotion for the anti-psychotic drug Abilify and use of kickbacks was part of a conspiracy to submit false claims.
The order leaves in place the appeals court’s majority decision not to revive former Bristol-Myers Squibb Co. sales representatives Joseph Ibanez and Jennifer Edwards’ False Claims Act suit, saying they hadn’t proven a link between alleged false statements and and claims submitted to the government.
The Supreme Court did not comment on the case...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!